Interferon-gamma is required for the late but not early control of Leishmania amazonensis infection in C57Bl/6 mice

Memorias do Instituto Oswaldo Cruz

Volumn 102, Issue 1, 2007, Pages 79-82

  Pinheiro, Roberta Olmo ^a   Rossi Bergmann, Bartira ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

C57Bl 6; Interferon gamma; Leishmania amazonensis

Indexed keywords

ANIMALIA; LEISHMANIA AMAZONENSIS; LEISHMANIA MAJOR; MUS;

EID: 33847168681     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762007000100013     Document Type: Article

References (26)

1. Afonso LC, Scott P 1993. Immune responses associated with susceptibility of C57Bl/10 mice to Leishmania amazonensis. Infect Immun 61: 2952-2959.
2. Aguilar Torrentera F, Lambot MA, Laman JD, Meurs MV, Kiss R, Noël JC, Carlier Y 2002a. Parasitic load and histopathology of cutaneous lesions, lymph node, spleen, and liver from BALB/c and C57Bl/6 mice infected with Leishmania mexicana. Am J Trop Med Hyg 66: 273-279.
3. Aguilar Torrentera F, Laman JD, Van Meurs M, Adorini L, Muraille E, Carlier Y 2002b. Endogenous interleukin-12 is critical for controlling the late but not the early stage of Leishmania mexicana infection in C57BL/6 mice. Infect Immun 70: 5075-5080.
4. Almeida RP, Barral-Netto M, de Jesus AMR, de Freitas LAR, Carvalho EM, Barral A 1996. Biological behavior of Leishmania amazonensis isolated from humans with cutaneous, mucosal, or visceral leishmaniasis in BALB/c mice. Am J Trop Med Hyg 54: 178-184.
5. Champsi J, McMahon-Pratt D 1988. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun 56: 3272-3279.
6. +T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection. Infect Immun 71: 3172-3182.
7. Convit J, Ulrich M, Fernandez CT, Tapia FJ, Caceres-Dittmar G, Castes M, Rondon AJ 1993. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 87: 444-448.
8. Green SJ, Meltzer MS, Hibbs JB Jr, Nacy CA 1990. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol 144: 278-283.
9. 2 in Leishmania amazonensis infection of BALB/c mice. Microbes Infect 8: 1219-1226.
10. Himmelrich H, Launois P, Maillard I, Biedermann T, Tacchini-Cottier F, Locksley RM, Rocken M, Louis JA 2000. BALB/c mice IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J Immunol 164: 4819-4825.
11. + regulatory T cells restrain pathogenic responses during Leishmania amazonensis infection. J Immunol 174: 6147-7153.
12. Liew FY, Wei XQ, Proudfoot L 1997. Cytokines and nitric oxide as effector molecules against parasitic infections. Philos Trans R Soc Lond B Biol Sci 352: 1311-1315.
13. Maioli TU, Takane E, Arantes RM, Fietto JL, Afonso LC 2004. Immune response induced by New World Leishmania species in C57Bl/6 mice. Parasitol Res 94: 207-212.
14. Padigel UM, Alexander J, Farrell JP 2003. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J Immunol 171: 3705-3710.
15. Pinheiro RO, Fonseca EF, Lopes JRC, Guedes HLM, Fentanes RF, Rossi-Bergmann, B 2005. TGF-b-associated enhanced susceptibility to leishmaniasis following intra-muscular vaccination of mice with Leishmania amazonensis antigens. Microbes Infect 7: 1317-1323.
16. Pinheiro RO, Pinto EF, Guedes HLM, Filho OA, de Mattos KA, Saraiva EM, Mendonça SC, Rossi-Bergmann B 2006. Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan. Vaccine in press.
17. Pinto EF, de Mello Cortezia M, Rossi-Bergmann, B 2003. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57Bl/6 mice against cutaneous leishmaniasis. Vaccine 21: 3534-3541.
18. Pinto EF, Pinheiro RO, Rayol A, Rossi-Bergmann B 2004. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK. Infect Immun 72: 4521-4527.
19. Qi H, Ji J, Wanasen N, Soong L 2004. Enhanced replication of Leishmania amazonensis amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis. Infect Immun 72: 988-995.
20. Reiner SL, Locksley RM 1995. The regulation of immunity to Leishmania major. Ann Rev Immunol 13: 151-177.
21. Rosas LE, Keiser T, Barbi J, Satoskar AA, Septer A, Kaczmarek J, Lezama-Davila CM, Satoskar AR 2005. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice. Int Immunol 10: 1347-1357.
22. Rossi-Bergmann B, Lenglet A, Bezerra-Santos CR, Costa-Pinto, D, Traub-Czeko, YM 1999. Use of fluorescent Leishmania for faster quantitation of parasite growth in vitro and in vivo. Mem Inst Oswaldo Cruz 94: 74.
23. Scott P 1991. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 147: 3149-3155.
24. + T cells on experimental infection of susceptible BALB/c mice with Leishmania amazonensis. Acta Trop 56: 111-120.
25. Soong L, Chang CH, Sun J, Longley BJ, Ruddle NH, Flavell RA, McMahon-Pratt D 1997. Role of CD4+ T cells in pathogenesis associated with Leishmania amazonensis infection. J Immunol 158: 5374-5383.
26. + effector cells default to the Th2 pathway in interferon-γ- deficient mice infected with Leishmania major. J Exp Med 179: 1367-1371.